Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and refreshing, because that oh-so familiar routine of online meetings, phone calls, and deadlines has returned. But you knew this would happen, yes? After all, the world, such as it is, continues to spin, albeit a bit wobbly at times. So perhaps we should give it a nudge in a better direction with a cup or three of stimulation. Our choice today is vanilla cinnamon. Please feel free to join us. Meanwhile, we have assembled a few items of interest to help you get started. We hope you have a smashing day and achieve your wildest dreams. And of course, please do keep in touch. …
Studies being used to decide whether the U.S. should authorize an ecstasy-based drug for traumatized patients missed serious side effects and were marked by bias, The Wall Street Journal reports. The U.S. Food and Drug Administration is expected within days to decide whether to approve the drug, known as MDMA, for treating post-traumatic stress disorder. Approval would be a milestone in decades of efforts to decriminalize the use of psychedelics. Three people who were subjects in the studies said their thoughts of suicide worsened during or after testing, but their downward slides weren’t captured in trial data and therefore not reflected in the final results.
All doses of Eli Lilly’s weight loss drug Zepbound and diabetes drug Mounjaro are now available, Reuters notes, citing an updated list from the U.S. Food and Drug Administration. However, the regulator has not yet removed the drugs off its shortages list. Lilly’s Mounjaro has been on the FDA shortages list since late 2022, while Zepbound was added to the list in April this year. The agency explained that even when all doses of a drug are listed as available, additional criteria are considered before moving a drug off the shortages list. These criteria include whether backorders have been fulfilled and if the supply is meeting demand.
